EXHIBIT 99.1 | |
Shire Pharmaceuticals Group plc Hampshire International Business Park, Chineham, Basingstoke RG24 8EP UK Tel +44 1256 894000 Fax +44 1256 894708 http://www.shire.com | ![]() |
16 June 2004 |
Shire Pharmaceuticals Group plc AGM – 2004
Results of the Annual General Meeting
Shire Pharmaceuticals Group plc held its Annual General Meeting today. All resolutions were put to the meeting and approved on a show of hands. The proxy votes received for the meeting are set out below:
For (including discretionary votes) | Against | tAbstention | ||
1. | To receive and consider the directors’ report and accounts for the year ended 31 December 2003 | 335,796,002 | 253,136 | 3,453,452 |
2. | To re-elect Dr James Henry Cavanaugh as a director | 332,639,514 | 6,778,765 | 84,311 |
3. | To re-elect Dr Barry John Price as a director | 331,615,623 | 6,771,673 | 1,115,294 |
4. | To elect Mr Robin William Turnbull Buchanan as a director | 332,648,452 | 6,770,518 | 83,620 |
5. | To elect Mr David John Kappler as a director | 332,650,302 | 6,765,130 | 87,158 |
6. | To re-appoint Deloitte & Touch LLP as Auditors and authorise the Audit Committee to fix their remuneration | 316,596,827 | 6,260,412 | 16,645,351 |
7. | To approve the Directors’ Remuneration Report | 321,854,131 | 12,283,161 | 5,365,298 |
8. | To authorise the allotment of shares | 330,958,287 | 2,845,855 | 5,698,448 |
9. | To authorise the disapplication of pre-emption rights | 332,351,240 | 1,273,952 | 5,877,398 |
10. | To authorise market purchases | 339,085,170 | 300,566 | 116,854 |
11. | To authorise donations to EU political expenditure political organisations and EU | 321,572,195 | 10,496,744 | 7,433,651 |
For further information please contact:
Investor Relations
Cléa Rosenfeld | +44 1256 894 160 |
Notes to editors
Shire Pharmaceuticals Group plc
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
For further information on Shire, please visit the Company’s website:www.shire.com